Journals / Türk Oftalmoloji Dergisi / 2012 / Cilt: 42 - Sayı: 3

Olası vogt-koyanagi-harada hastalığı olgusu

A case of probable vogt-koyanagi-harada disease

Pages
235–237
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Immunomodulatory and immunosuppressive drug therapies are necessary to prevent corticosteroid-associated complications as well as recurrence of VKH disease. (Turk J Oph thal mol 2012; 42: 235-7)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this article is to present a rare form of Vogt-Koyanagi-Harada (VKH) disease.
📊
Key Findings & Data:A 58-year-old woman presented with bilateral painless blurred vision and headache.
💡
Conclusion & Impact:Immunomodulatory and immunosuppressive drug therapies are necessary to prevent corticosteroid-associated complications as well as recurrence of VKH disease. (Turk J Oph thal mol 2012; 42: 235-7)
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

The aim of this article is to present a rare form of Vogt-Koyanagi-Harada (VKH) disease. The complete and incomplete forms of VKH disease are more frequent than the probable form. A 58-year-old woman presented with bilateral painless blurred vision and headache. The patient’s visual acuity was 1/10 for both eyes. The patient had bilateral iridocyclitis, optic disc swelling, serous retinal detachment and choroidal thickening. The examinations by specialists in otorhinolaryngology, neurology, dermatology, rheumatology and chest diseases revealed no abnormal findings. Cerebrospinal fluid examination was also normal. After the diagnosis of probable VKH disease, the patient was treated with systemic pulse corticosteroid and cyclosporine-A. After this treatment, the abnormal findings were resolved and her visual acuity was improved to 10/10 for both eyes. VKH patients should be followed closely for risk of disease recurrence and side effects of medications. Immunomodulatory and immunosuppressive drug therapies are necessary to prevent corticosteroid-associated complications as well as recurrence of VKH disease. (Turk J Oph thal mol 2012; 42: 235-7)

Özet

Bu makalenin amacı Vogt-Koyanagi-Harada (VKH) hastalığının nadir bir formunu sunmaktır. VKH hastalığının tam ve tam olmayan formları olası formuna göre daha sıktır. Elli sekiz yaşında kadın hasta baş ağrısı ve iki taraflı ağrısız görme bulanıklığı ile başvurdu. Hastanın görme düzeyi her iki göz için 1/10 idi. Hastada; iki taraflı iridosiklit, optik disk ödemi, seröz retina dekolmanı ve koroidal kalınlaşma vardı. Kulak burun boğaz, nöroloji, dermatoloji, romatoloji ve göğüs hastalıkları muayeneleri normaldi. Beyin omurilik sıvısı incelemesi de normaldi. Olası VKH hastalığı tanısı konulduktan sonra, hasta sistemik puşe kortikosteroid ve siklosporin-A ile tedavi edildi. Bu tedaviden sonra anormal bulgular geriledi ve hastanın görme düzeyi her iki göz için 10/10’ a yükseldi. VKH hastaları; hastalık tekrarlama riski ve tedavilerin yan etkileri açısından yakın takip edilmelidirler. İmmünmodülatör ve immünsüpresif ilaç tedavileri, hem kortikosteroid ilişkili komplikasyonların hem de VKH hastalığının tekrarlamasının önlenmesi için, gereklidirler. (Turk J Oph thal mol 2012; 42: 235-7)

🔖

Cite This Article

YILDIRIM, C., AVUNDUK, A. M., ACAR, M., YAYLALI, V. (2022). Olası vogt-koyanagi-harada hastalığı olgusu. Türk Oftalmoloji Dergisi, Cilt: 42 - Sayı: 3, 235–237. https://ajindex.com/articles/638235

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Fang W, Yang P. Vogt-koyanagi-harada syndrome. Curr Eye Res. 2008;33:517-23
  2. Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2005;45:115-34
  3. Damico FM, Bezerra FT, Silva GC, Gasparin F, Yamamoto JH. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol. 2009;72:413-20
  4. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46:111-22
  5. Mirza GE. Sarkoidoz, sempatik oftalmi, Vogt-Koyonagi-Harada sendromu. Turkiye Klinikleri J Ophthalmol-Special Topics. 2008;1:51-61
  6. Ceylan OM, Uysal Y, Türk A, Gökçe G, Erduman C, Sobacı G. Vogt-Koyanagi-Harada Sendromlu Olguların Klinik Özellikleri. Turk J Ophthalmol. 2010;40:250-4
  7. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol. 2005;20:183-90
  8. Rao NA. Pathology of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:81-5
  9. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-52. 10. da Silva FT, Damico FM, Marin ML, et al. Revised diagnostic criteria for vogt-koyanagi-harada disease: considerations on the different disease categories. Am J Ophthalmol. 2009;147:339-45
  10. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78:223-6
  11. Islam SM, Numaga J, Fujino Y, et al. HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:3890-6
  12. Hayasaka Y, Hayasaka S. Almost simultaneous onset of Vogt-Koyanagi-Harada syndrome in co-workers, friends, and neighbors. Graefes Arch Clin Exp Ophthalmol. 2004;242:611-3
  13. Sugita S, Takase H, Kawaguchi T, Taguchi C, Mochizuki M. Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:87-95
  14. Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol.2001;131:599-606.